JNJ Johnson & Johnson
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 12-month channel rising
Price is between the lines.
- 12-month channel
- US$248.57 – US$296.27 · rising, +38% a year
- Price in channel
- 52% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$295.97
- Turns bearish below
- US$248.37
Price history, with the path projected 3 months forward
Updated 7:22 PM ET (17 h ago)
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- The same lines over the last 12 months
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
Hit rate too low on this symbol (2/6) — no published call or alerts; levels below are for reference.
Buy at or below
US$258.20
level as at 30 Nov 2026
Our target
US$296.92
by 13 Dec 2026
Projected move
15.0%
gross, before costs
Price is between our buy and target.
Target: JNJ's usual move size (15.0%), the best return per day on this path.
6 settled calls · 2 reached target (33.3%) · average best move 4.8%. See the full record.
- Upper line touches
- 4
- Lower line touches
- 5
- Fit confidence
- 74%
- Fitted
- 1 Nov 2026
Company information
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato
- Employees
- 141,700
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- 23/100
- Profitability
- 68/100
- Financial health
- 63/100
- Cash generation
- 54/100
Key statistics
- Market cap
- US$641.07B
- Enterprise value
- US$668.81B
- Beta
- 0.23
- Avg volume
- 7.60M
- Revenue per share
- 40.59
- Dividend yield
- 1.98%
- 52-week range
- 184.66-281.07
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 40.37
- PEG
- -1.10
- Price / sales
- 6.45
- Price / book
- 7.99
- EV / EBITDA
- 21.71
- Gross margin
- 68.81%
- Operating margin
- 25.70%
- Net margin
- 16.20%
- Current ratio
- 1.02
- Quick ratio
- 0.74
- Debt / equity
- 0.55
- Interest cover
- 31.99
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$94.19B | US$63.94B | US$25.60B | US$26.80B | US$11.03 |
| 2024 | US$88.82B | US$61.35B | US$22.15B | US$14.07B | US$5.79 |
| 2023 | US$85.16B | US$58.61B | US$23.41B | US$35.15B | US$13.72 |
| 2022 | US$79.99B | US$55.39B | US$21.01B | US$17.94B | US$6.73 |
| 2021 | US$78.74B | US$55.34B | US$20.94B | US$20.88B | US$7.81 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$199.21B | US$117.67B | US$81.54B |
| 2024 | US$180.10B | US$108.61B | US$71.49B |
| 2023 | US$167.56B | US$98.78B | US$68.77B |
| 2022 | US$187.38B | US$110.57B | US$76.80B |
| 2021 | US$182.02B | US$108.00B | US$74.02B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$24.53B | US$19.70B | US$26.80B |
| 2024 | US$24.27B | US$19.84B | US$14.07B |
| 2023 | US$22.79B | US$18.25B | US$13.33B |
| 2022 | US$21.19B | US$17.18B | US$17.94B |
| 2021 | US$23.41B | US$19.76B | US$20.88B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$10.80 | US$93.76B | 17 |
| 2026 | US$11.11 | US$101.21B | 11 |
| 2027 | US$11.60 | US$107.93B | 12 |
| 2028 | US$13.97 | US$116.71B | 5 |
| 2029 | US$15.71 | US$125.59B | 1 |
| 2030 | US$17.70 | US$135.57B | 1 |
Analyst view
- Target (mean)
- US$285.31
- Target (high)
- US$320.00
- Target (low)
- US$260.00
- Strong buy
- 0
- Buy
- 21
- Hold
- 16
- Sell
- 3
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.